Neuroinflammation of the brain is a progressive secondary event following the primary event of traumatic brain injury (TBI) and a major factor in lingering neurological deficits stemming from TBI. The unique traumatic injury suffered by each victim of TBI-and the contradictory effects of neuroinflammation on the neurological outcome of the victims-complicates efforts to develop broad pharmacological treatments for traumatic brain injury.
During incidents of trauma like TBI, immune and inflammatory cells permeate the blood-brain barrier (BBB) to protect neural tissue. However, this inflammation may lead to secondary cascades that release neurotoxic substances.
No pharmacological treatment to date has been approved to counteract the effects of secondary brain injury following TBI, but with a better understanding of the mechanisms that cause both the beneficial and deleterious effects of neuroinflammation, researchers can design these future neuroprotective drugs.
Finnie J. Neuroinflammation: beneficial and detrimental effects after traumatic brain injury. Inflammopharmacol. (January 2013).